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Edited by Sandro SonninoAbstract Understanding the molecular mechanism of host-
pathogen interactions is the basis for drug design and vaccine
development. The ﬁne composition of mycolic acids (MA), the
major constituents of Mycobacterium tuberculosis (Mtb) cell
envelope, as well as other cell wall-associated lipids, contribute
to determine the virulence of a given strain. However, endoge-
nous receptors for mycolic acids on susceptible cells exposed to
mycobacterial infections have not been fully identiﬁed. Here,
we show that galectin-3, a multifunctional b-galactoside binding
lectin present mainly in the cytoplasm of inﬂammatory cells and
also present on the cell surface, can recognize mycobacterial my-
colic acids. MA can inhibit the lectin self-association but not its
carbohydrate-binding abilities and can selectively interfere in the
interaction of the lectin with its receptors on temperature-sensitive
dendritic cell line, suggesting that galectin-3 could be involved in
the recognition of traﬃcking mycolic acids and participate in
their interaction with host cells.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
Keywords: Galectin-3; Mycobacteria; Mycolic acids; Fas
binding1. Introduction
The cell envelope of Mycobacterium tuberculosis (Mtb) is
composed mainly of lipids, which are unique in composition
[1] and are associated with mycobacterial virulence. In fact
the lipid heterogeneity, rather than genetic variations, is be-
lieved to be the major cause of diﬀerences in pathogenicity be-
tween strains [2–4]. It has been shown that complex lipids and
glycolipids can be actively released from the mycobacterial cell
into the cytoplasm of a host cell. They can also be secreted into
the extra cellular space and interact with bystander uninfected
cells [5]. Mycolic acids (MA) are a-alkyl-b-hydroxyl fatty acids
and are the major lipid constituents of the Mtb hydrophobic
barrier responsible for resistance to drugs and to oxidative
stress [6,7]. They can be either covalently attached via arabino-
galactan (AG) to the cell wall peptidoglycan, or non-covalently
associated like trehalose dimycolate (TDM) [8]. Although it is
known that MA can have an active role in the host–pathogenAbbreviations: Gal-3, galectin-3; MA, mycolic acids; LPS, lipopoly-
saccharides
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doi:10.1016/j.febslet.2005.11.005interaction [9], their receptor(s) on cells susceptible to myco-
bacterial infection have not however been characterized.
Galectin-3 (Gal-3, Mac-2, IgE BP), a member of the growing
family of animal lectins speciﬁc for beta-galactosides, is a sol-
uble protein composed of a C-terminal carbohydrate-recogni-
tion-domain (CRD) and a N-terminal domain, containing
multiple repeats of a sequence rich in glycine, proline, and
tyrosine (for review see [10]). Galectin-3 is able to self-associ-
ate, through its N-terminal, upon binding to glycoconjugate li-
gands [11]. Galectin-3 expression is upregulated after some
bacterial and parasitic infection [12,13] and can be modulated
by modiﬁed lipoproteins [14]. This lectin is found in the cyto-
plasm of many cell types, especially inﬂammatory cells, such as
macrophages, dendritic cells, mast cells, neutrophils and eosin-
ophils [15,16], can translocate into the nucleus [17] and is also
secreted on the cells surface and into the extra-cellular milieu
[18]. Galectin-3 is implicated in several diﬀerent biological pro-
cesses ranging from cell growth and proliferation, apoptosis in
cells of the immune system to acting as an adhesion promoter
during cell inﬁltration of inﬂamed tissues [19–21]. These prop-
erties might have a direct or indirect inﬂuence on the course of
mycobacterial infections. Recently, galectin-3 has been shown
to interact with mycobacterial phosphatidylinositolmannans
(PIMs) in infected macrophages [22]. In this study, we show
for the ﬁrst time, by direct binding assays, that galectin-3 also
recognises speciﬁcally the mycolic acids components of the
Mtb cell wall. Binding to mycolic acids inhibits the oligomer-
ization of galectin-3 in vitro without altering its carbohy-
drate-binding abilities and interferes with speciﬁc receptors
of the lectin on dendritic cells.2. Materials and methods
2.1. Chemicals
Recombinant hamster galectin-3 was obtained by bacterial expres-
sion followed by puriﬁcation on immobilised lactose aﬃnity column
[23]. Galectin-3 carboxy-terminal fragment (CRD) (residues 104–245)
was obtained by digestion of the full-length protein with bacterial col-
lagenase followed by puriﬁcation as above. Murine EHS tumor lami-
nin, lipopolysaccharides fraction from Escherichia coli 0111:B4 strain
and its ﬂuorescein isothiocyanate conjugated (LPS-FITC) and mycolic
acids (Mtb human strain) were all from Sigma–Aldrich, UK. Endo-
toxin-free lipoarabinomannan (LAM) and arabinomannan (AM)
(strain H37Rv) were kindly donated by Dr. Ruth Griﬃn (Imperial Col-
lege, London, UK). Total lipids (TLP), obtained by chloroform/meth-
anol (2:1) extraction and endotoxin-free phosphatidylinositolmannan
(PIM) (H37Rv strain) were from TB Research Material and Vaccine
Testing, Colorado State University. Rabbit polyclonal antibody againstblished by Elsevier B.V. All rights reserved.
Fig. 1. SPR analysis of the binding of components of M. tuberculosis
membranes to immobilised galectin-3. Samples of puriﬁed mycobac-
terial cell wall components (30 ll, 0.5–0.7 mg/ml) were passed individ-
ually at 10 ll/min through a multichannel chip derivatized with
galectin-3. (1) phosphatidylinositolmannan (PIM); (4) lipoarabino-
mannan (LAM); (5) mycolic acids (MA); (6) total lipids, included
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galectin-3 antibody (a-Mac2) was from culture supernatants of the
M3/M38 hybridoma (ATCC TIB 166, Rockville, MD). All anti-galec-
tin-3 antibodies were puriﬁed by aﬃnity chromatography on Protein-
G-Agarose (Pierce/Perbio Science, UK Ltd.).
Puriﬁed antibodies against mouse MHC I (H-2Kk), MHC II (M5/
114.15.2), CD1d (CD-1, Ly-38), CD95 (Fas, Jo2) were from BD-Bio-
sciences (Pharmingen), Cowley, Oxford, UK.
All other chemicals, when not speciﬁed were from Sigma.
2.2. Binding assays
Direct binding experiments were performed on a BIAcore 2000
instrument (BIAcore, Uppsala, Sweden) as previously described
[25,26]. Brieﬂy the methodology used is based on surface plasmon res-
onance (SPR) applied to an optical biosensor, which enables real time
detection of molecular association and dissociation reactions by mon-
itoring change in refractive index caused by alteration in mass on the
optical sensor. The refractive index change is represented as response
units (RUs) in a sensogram, which is proportional to the amount of
analyte (injected in mobile phase) binding to ligand immobilised on
the sensor surface. Galectin-3 or other proteins as indicated, was cova-
lently coupled to a CM5 Sensor Chip (BIAcore) following the manu-
facturers instructions. Control ﬂow-cells consisted of immobilised
bovine serum albumin (BSA). The analytes were dissolved in PBS
and injected at a ﬂow rate of 10 ll/min at 25 C using the multichannel
mode. Regeneration of the sensor surface was achieved by short pulses
of 0.1 M lactose or/and repeated washes with buﬀer. Data analysis was
performed with BIAcore 3.0 evaluation software.
2.3. Cells
A temperature-sensitive mouse dendritic cell line (ts-DC), a gift of
Dr. B. Stockinger [27], was grown at 35.5 C in Iscoves Modiﬁed
Dulbeccos medium supplemented with 5% heat-inactivated FCS,
4 mM L-glutamine and 50 lM 2-mercaptoethanol.
2.4. Flow cytometry
FACS analyses were performed on a FACSCalibur Becton Dickin-
son instrument. Fixed ts-DC (1 · 105–1 · 106) were incubated with
ﬂuorescein isothiocyanate-conjugated LPS (LPS-FITC) (2–3 lg/ml)
for 2 h at room temperature. In some experiments 10 lg/ml of rat
monoclonal or rabbit polyclonal a-galectin-3 antibodies (detoxiﬁed
with AﬃnityPak Detoxi-Gel from Perbio Science, UK Ltd.) were
added. For negative controls and isotype match the cells were incu-
bated with unconjugated LPS with or without rat IgG2a isotype, when
monoclonal anti-galectin-3 antibody was used, or rabbit IgG when
polyclonal anti-galectin-3 antibody was used. In other experiments
the incubation mixture contained 10 lg/ml of mycolic acids.
2.5. IL6 determination
1 · 105 cells (ts-DC) were grown in 12-wells plates for 24 h before
addition of LPS (0.1 ng/ml) with or without anti-galectin-3 antibody
or mycolic acids (10 lg/ml). IL6 concentrations were determined by
using the dedicated kit from eBioscience following the manufacturers
instructions. Benchmark Plus microplate reader (Bio-Rad) was used
for the ﬁnal reading.
2.6. Extraction of membrane proteins
1 · 108–1 · 109 cells (ts-Dc) were biotinylated using cleavable biotin
disulﬁde N-hydroxysuccinimide ester (Sigma biotinylation kit) follow-
ing the manufacturers instructions. The extent of the reaction was as-
sessed by ﬂow cytometry using ﬂuorescein isothiocyanate-conjugated
streptavidin (Pierce/Perbio Science). The cells were lysed with RIPA
buﬀer (50 mM Tris–HCl, pH 8.0, 150 mM NaCl, 5 mM EDTA,
0.5% sodium deoxycolate, 1.0% NP-40, and 0.1% SDS) over-night
and after clariﬁcation the lysate was applied to an avidin-agarose col-
umn. The membrane proteins were eluted with 50 mM dithiothreitol
(DTT) in PBS, dialysed against PBS and frozen until further use.trehalose dimycolate and sulpholipids (TLP); (7) arabinomannan
(AM); (2) E. coli LPS and (3) laminin, used as positive controls, are
also shown. All the curves have been corrected for the unspeciﬁc bulk
binding. The arrows indicate the beginning and the end of the
injection. Each sensogram is a typical example of at least three
independent experiments.2.7. Immuno-precipitation and Western blots
Monoclonal antibodies used for immuno-precipitation were cova-
lently cross-linked to protein-G-agarose by dimethyl pimelimidate
[28]. The beads (1 ml packed volume) were mixed with the membraneprotein solution (0.7–1.5 ml at 1 mg/ml) and incubated over-night at
4 C. After extensive washes with PBS the speciﬁcally bound proteins
were eluted from the antibody with triﬂuoroacetic acid (TFA) 0.1–
0.2%. The pooled fractions were freeze-dried and dissolved in the
appropriate volume of sample buﬀer for gel electrophoresis. Western
blot analyses were performed using the puriﬁed monoclonal antibodies
described earlier and the enhanced chemiluminescence detection sys-
tem (Amersham Biosciences, UK Ltd.).3. Results
3.1. Direct binding of M. tuberculosis cell envelope components
to galectin-3
We used surface plasmon resonance technology (SPR) to
test the ability of various constituents of the mycobacterium
cell wall to bind galectin-3.
Puriﬁed components of Mtb cell envelope (30 ll at about
0.5 mg/ml) were injected separately, at 10 ll/min, over immo-
bilised recombinant hamster galectin-3 (and simultaneously
over the control ﬂow cell) and their sensograms recorded.
As Fig. 1 shows total lipids (TLP), phosphatidylinositolman-
nan (PIM) and lipoarabinomannan (LAM) fractions all
bound to immobilised galectin-3 whereas the delipidated frac-
tion, arabinomannan (AM), did not. These data suggest that
a hydrophobic domain is essential for the association to the
protein, presumably in a carbohydrate-independent manner.
Fig. 1 also shows the binding of the MA fraction. As positive
control we show laminin, a glycoprotein of the extra-cellular
matrix, whose carbohydrate-dependent binding to galectin-3
CRD has been well characterised [29,25]. Another positive
Fig. 2. Kinetic analyses of the binding of MA and LPS to immobilised galectin-3 and its C-terminal (CRD). Increasing concentrations (up to 5 mg/
ml) of MA (A) and LPS (B) were injected over ﬂow-cells coated with either galectin-3 (Gal-3) or its C-terminal domain (CRD). It is evident that while
MA give comparable signals for the full lectin and for the CRD the LPS response for the truncate lectin is negligible. The light traces at the bottom
are examples of the response on the reference cell. Insets: Scatchard plots of the binding of MA (mM) (A) and LPS (mg/ml) (B) on full galectin-3
(ﬁlled dots) and on the CRD (crosses). Representative example of two or three independent experiments.
Fig. 3. Eﬀect of mycolic acids (MA) and LPS on the binding of
galectin-3 to immobilised laminin. A ﬁxed amount of galectin-3 (1 lM)
(A) or C-terminal (CRD) (3 lM) (B) was mixed with various
concentrations of MA (A,B) or E. coli LPS (A inset) and passed
separately over a sensor chip coated with laminin. Bottom curve in A
(Gal-3 = 0) shows the lack of binding of MA alone (0.7 mg/ml) to
laminin. Inset: plot of the response (RU%) against the concentration of
the bacterial ligand. The measurements were taken at the end of the
association phase, after subtraction of the non-speciﬁc binding. Data
are a representative example of two independent experiments.
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class of bacterial compounds that are known to interact with
the N-terminal domain of galectin-3 through their hydropho-
bic lipid A and can also interact with the lectin C-terminal
fragment (CRD) through a beta-galactoside-containing poly-
saccharide [30,31].
We compared the kinetics of binding of MA and LPS using
a multichannel sensor chip consisting of ﬂow cells individually
derivatized with full galectin-3, galectin-3 CRD and BSA
(Fig. 2). MA gave comparable response for the full lectin
and its CRD (Fig. 2A): the Scatchard plot (Fig. 2A inset)
was linear for the full lectin (KA = 10
4 M1, assuming for
MA an average molecular mass of 1200 Da), while it was
bell-shaped, indicating positive cooperativity [32], for the
CRD (KA ranging from 10
3 to 104 M1). This suggests that
the N-terminal of the protein is directly involved in the inter-
action with MA and modulates the way MA associate with
the CRD. In contrast, our SPR data show that the LPS used
in this study has very little aﬃnity for galectin-3 CRD
(Fig. 2B), but exhibits a positive cooperativity in its interaction
with the full-length protein (Fig. 2B inset); these results are in
agreement with some in vivo experiments that indicated an
non-saturable binding of LPS-FITC to monocytes through
CD-14-independent interactions [33].
3.2. MA inhibit galectin–galectin self-association, but not the
galectin-3-carbohydrate-binding abilities
We next examined the eﬀect of binding of mycolic acids on
the interaction of galectin-3 with its well-deﬁned ligand,
namely laminin. Solutions containing ﬁxed concentrations of
galectin-3, or of its C-terminal CRD (1–3 lM) together with
various concentrations (from 0.1 to 1.0 mg/ml) of MA or, as
control, LPS, were injected over a ﬂow cell derivatized with
laminin (Fig. 3).
With intact galectin-3 we observed a reduction of the SPR
response at low concentrations of both MA (Fig. 3A) and
LPS (Fig. 3A inset), which reached a minimum and then in-
creased with the concentration. Previous studies [11,34] have
shown that galectin-3 bound through its CRD to laminin
can recruit additional galectin-3 by carbohydrate-independent
molecular interactions involving the N-terminal domain. Ourpresent data (Fig. 3) suggest an initial inhibition of the forma-
tion of galectin-3 aggregates on a laminin substratum by the
binding of MA/LPS, followed by the association of these
6752 E. Barboni et al. / FEBS Letters 579 (2005) 6749–6755hydrophobic ligands to the monomeric lectin. In fact when we
used the CRD fragment, that remains mainly monomeric after
binding to laminin, the mixtures of CRD plus MA produced
greater signals than the CRD alone (Fig. 3B). This is expected
given the association of MA with the CRD and the fact that
the SPR response is proportional to the molecular mass of
the binding complex. LPS in this latter case had no or very
small eﬀect, due to its poor aﬃnity for the galectin-3 CRD
(data not shown). These data also indicate that MA interact
with galectin-3 C-terminal fragment (CRD) in a carbohy-
drate-independent-manner and do not dissociate the lectin
from laminin.
3.3. MA and LPS follow diﬀerent pathways on ts-DC
Infection with Mtb is most common in the lungs, where the
mycobacterium is phagocytosed by alveolar macrophages. This
region is also rich in immature dendritic cells that are recruited
and initiate the cell-membrane immune response [35]. Den-
dritic cells (DC) express high levels of galectin-3 on the cell sur-
face. In order to test if MA might compete with LPS in
interactions on the cell surface, since they are both recognised
by galectin-3, we used temperature-resistant cell line (ts-DC),
which has the phenotype of immature DC [24].Fig. 4. Interaction on dendritic cells. Ts-DC were stained with FITC conjug
10 lg/ml) (A), or MA (10 lg/ml) (B) and analysed by FACS. (A) Shadow
IgG2a); continuous traces = LPS-FITC and non-immune rat IgG2a; lighter d
traces = negative control (unconjugated LPS); continuous traces = LPS-FITC
independent experiments. (C) IL6 released from ts-DC activated for 24 h wi
polyclonal anti-galectin-3 antiboby (Ab 33, 66 lg/ml) or MA (10 lg/ml). Dat
two times.Ts-DC were labelled with FITC conjugate-LPS (LPS-FITC)
in the presence or absence of a rat monoclonal anti-galectin-3
antibody (a-Mac2), speciﬁc for epitopes on the N-terminal of
galectin-3 (Fig. 4A), or in presence or absence of mycolic acids
(Fig. 4B) and analysed by ﬂow cytometry. The anti-galectin-3
antibody inhibited signiﬁcantly the binding of LPS to the cell
surface. Since LPS binds mainly to the N-terminal domain
of galectin-3 (Fig. 2), this result is consistent with the sugges-
tion that galectin-3 expressed on the cell surface participates
in LPS attachment to the cells membrane. By contrast MA
had no eﬀect on LPS binding. Similarly the production of
IL6 by ts-DC after stimulation for 24 h with 0.1 ng/ml of
LPS, was reduced in a dose-dependent manner by anti-galec-
tin-3 antibody, whereas MA had no eﬀect (Fig. 4C). These re-
sults, taken together, suggest that binding of mycolic acids and
LPS on ts-DC is independent.
3.4. MA interfere with galectin-3-Fas interaction
On the cell surface galectin-3 interacts with a growing num-
ber of ligands (see review [20]). In order to assess further the
possible role of galectin-3 on cells susceptible to mycobacterial
infection, we ﬁrst characterised some of the proteins associated
with the lectin on ts-DC.ated LPS (2–3 lg/ml) with and without rat a-galectin-3 mAb (a-Mac2
ed traces = negative control (unconjugated LPS and non-immune rat
otted traces = LPS-FITC plus rat anti-galectin-3 mAb. (B) Shadowed
; lighter dotted traces = LPS-FITC plus MA. Typical example of three
th 0.1 ng/ml of LPS in the absence (100%) or presence of either rabbit
a are the means ± S.D. (n = 3) of a representative experiment repeated
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an anti-galectin-3 monoclonal antibody (a-Mac2) column were
analysed by SDS–PAGE and Western blotting. Among the
proteins co-precipitated with galectin-3 we could identify some
unexpected receptors, such as MHC class I, MHC class II and
CD1, that are reportedly involved in the presentation of
endogenous, exogenous and hydrophobic antigens, respec-
tively, as well as Fas (APO-1, CD95), apoptosis-mediating sur-
face antigen, member of the death receptor family (Fig. 5A).
Fas interaction with galectin-3 has been recently described
by other authors [36], while the direct association of galectin-
3 with the antigens presenting complexes had never been
shown before, although dendritic cells-derived exosomes had
been shown to contain galectin-3 together with MHC I and
MHC II [37].
All the antibodies against the molecules identiﬁed were able
to pull down galectin-3 in similar immuno precipitation exper-
iments (data not shown).
To assess the eﬀect of mycolic acids on the association of
galectin-3 to its receptors, one half of cell lysate (0.5–0.7 ml)
was incubated with mycolic acids (200 lg/ml) over night at
4 C with gentle stirring. The other half was kept in the same
conditions and used as a reference. After clariﬁcation the solu-
tions were immuno-precipitated with the same amount of anti-
galectin-3 beads and equal amounts of the total eluates were
analysed by SDS–PAGE and Western blotting. Screening with
the antibodies against the proteins identiﬁed revealed that MAFig. 5. Identiﬁcation of new receptors for galectin-3 on ts-DC and
eﬀect of MA on galectin-3-Fas interaction. Membrane proteins
extracted from ts-DC were immuno precipitated with anti-galectin-3
mAb (a-Mac2) beads. (A) The eluate from the antibody column was
analysed by 12% SDS–PAGE and Western blotting using the
antibodies against the molecules indicated at the top of each gel.
Molecular mass markers at the left of the picture. (B) Western blot
analysis with a-Fas mAb of the membrane proteins immuno-precip-
itated in absence () and in presence (+) of mycolic acids. One half of
cells lysate was incubated with mycolic acids prior immuno-precipi-
tation with a-Mac2 mAb, the other half was used as control. To assess
the equivalence of the loading the gels were stripped and redeveloped
with a-Mac2 mAb (shown at the bottom of the gels). The experiment
was repeated twice with similar result.act speciﬁcally on the association of galectin-3 with Fas, reduc-
ing the amount of this proteins that co-precipitates with the
lectin (Fig. 5B). This suggests that the Fas-galectin-3 interac-
tion can be one of the targets of mycolic acids on dendritic cell
surface.4. Discussion
M. tuberculosis is still a threat to human health. The insur-
gence of Mtb drugs resistance calls for a better understanding
of molecular interactions between the bacterium and infected
cells.
Here we show that galectin-3, a well-known member of the
galectin family is able to recognise the lipid moiety of the ma-
jor components of Mtb cell envelope (Fig. 1). While the asso-
ciation of galectin-3 with mycobacterial PIM in BCG-infected
macrophage has been reported previously [22], the direct
interaction of the lectin with mycolic acids is a totally new
ﬁnding. We have analysed the binding of mycolic acids
(MA) to galectin-3 in vitro and have found that MA not only
associates to the covalently immobilised protein (Fig. 2A), but
still binds if galectin-3, in solution phase, is involved in a car-
bohydrate-dependent interaction with immobilised laminin
(Fig. 3). The inhibition of galectin–galectin association
(Fig. 3A inset: descending phase) could potentially aﬀect all
the processes modulated by galectin-3 in its multivalent form
and depending on the equilibrium between its various oligo-
mers [38,39], while the accumulation of MA on the laminin-
bound galectin-3 (Fig. 3A inset: ascending phase) suggests
that MA are eﬀectively cross-linked by galectin-3 to the
immobilised glycoprotein and supports the hypothesis that
galectin-3 could play a role in the opsonization of mycobacte-
rial material [22]. The interpretation of the SPR response
shown in Fig. 3 is conﬁrmed by the behaviour of LPS in
the same conditions: in fact LPS associates mainly with the
N-terminal of the immobilised lectin (Fig. 2B) and aﬀects
the binding of galectin-3 to laminin in a way similar to that
of MA (Fig. 3A inset), indicating that the interactions of these
ligands with the N-terminal of galectin-3 are responsible for
the biphasic shape of the curve, while the lectins association
with laminin, that occurs through the carbohydrate-binding
pocket of the CRD, is not involved.
At this point, we investigated the possibility that MA and
LPS could share the same receptors on the cell surface, since
they both bind galectin-3. Since on ts-DC the anti-galectin-3
antibody blocks the attachment of LPS to the cell surface
(Fig. 4) and inhibits the release of IL6, the extracellular galec-
tin appears to participate in the attachment of LPS. In contrast
MA has no eﬀect, indicating that it follows a diﬀerent route.
This interpretation is in agreement with a recent report by
Korf et al. [40] where the authors exclude the involvement of
TLR4, the receptor for LPS, as mycolic acids recognition
receptor on macrophages.
We then tested the hypothesis that galectin-3 might function
as a soluble carrier helping the hydrophobic ligands to assume
a unique conformation recognised by speciﬁc receptor(s) on
the cells surface and that MA might interfere with some inter-
action between galectin-3 and its cell receptors. In fact we
found that MA speciﬁcally inhibit the binding of galectin-3
to endogenous Fas on ts-DC cell line (Fig. 5), suggesting that
this interaction might be the target of mycolic acids on DC cell
6754 E. Barboni et al. / FEBS Letters 579 (2005) 6749–6755membrane. Galectin-3 contains the anti-death-motif conserved
in the BH1 domain of the Bcl-2 proteins [41] and other authors
have demonstrated that its association with Fas determines the
type of apoptotic pathway that will be selected by the cell [37].
It has been reported, on the other hand, that M. tuberculosis-
infected macrophages show reduced susceptibility to FasL-in-
duced apoptosis [42].
Although further studies are needed to clarify whether the
association between galectin-3 and mycolic acids plays a direct
role in the modulation of the apoptotic process and whether
this lectin is involved in the antigens presenting mechanism(s),
as suggested by its co-precipitation with MHC I, MHC II and
CD1 (Fig. 5A), this work demonstrates a novel interaction be-
tween host carbohydrate-binding proteins and mycobacterial
lipids, that could be extremely valuable for the identiﬁcation
of bacterial targets and for drugs design.
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